Endurant Capital Management’s Integra LifeSciences IART Stock Holding History

Endurant Capital Management’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-281,608	Closed	-$13.3M	–	64
2020 Q3	$13.3M	Buy	+281,608	New	+$13.4M	3.93%	6
2019 Q4	–	Sell	-84,225	Closed	-$5.06M	–	63
2019 Q3	$5.06M	Buy	84,225 +41,398	+97%	+$2.47M	1.82%	19
2019 Q2	$2.39M	Buy	+42,827	New	+$2.21M	0.94%	32

Other funds holding IART

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

EVM

Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Endurant Capital Management's IART Position: Q4 2020 in Review

Endurant Capital Management sold out of Integra LifeSciences (IART) in Q4 2020, closing a stake of 281,608 shares — an estimated $13.3M sold.

Endurant Capital Management first reported a position in IART in Q2 2019 and held it in 3 quarters. The position peaked at $13.3M in Q3 2020. 251 funds tracked by Wall St. Rank hold IART as of Q4 2020.

Endurant Capital Management reported no remaining Integra LifeSciences position as of Q4 2020 after selling out during the quarter.
Endurant Capital Management sold 281,608 Integra LifeSciences shares in Q4 2020, an estimated $13.3M.
Endurant Capital Management first reported a position in Integra LifeSciences in Q2 2019 and held it in 3 quarters.
Endurant Capital Management's Integra LifeSciences position peaked at $13.3M in Q3 2020.
251 funds tracked by Wall St. Rank held Integra LifeSciences as of Q4 2020.

Based on Endurant Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.